Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Return on Invested Capital (2022 - 2026)

MoonLake Immunotherapeutics' Return on Invested Capital history spans 5 years, with the latest figure at 0.01% for Q1 2026.

  • Quarterly Return on Invested Capital changed 0.0% to 0.01% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Invested Capital came in at 0.01% for Q1 2026, down from 0.01% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.1% in Q1 2022 to a low of 0.03% in Q2 2022.
  • The 5-year median for Return on Invested Capital is 0.0% (2025), against an average of 0.0%.
  • The largest YoY upside for Return on Invested Capital was 2bps in 2023 against a maximum downside of -11bps in 2023.
  • MoonLake Immunotherapeutics' Return on Invested Capital stood at 0.01% in 2022, then skyrocketed by 87bps to 0.0% in 2023, then plummeted by -181bps to 0.0% in 2024, then plummeted by -118bps to 0.01% in 2025, then decreased by -11bps to 0.01% in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Return on Invested Capital are 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).